Journal
MOLECULAR PHARMACEUTICS
Volume 9, Issue 12, Pages 3543-3550Publisher
AMER CHEMICAL SOC
DOI: 10.1021/mp300382n
Keywords
ceria nanoparticles; PET; pharmacokinetics; in vivo evaluation; rodent
Funding
- Spanish MICINN [CTQ-2009-11586, CTQ2006-06785, CTQ2007-67805-AR07, PI10/1195, AP192/11]
- Fondo de Investigacion Sanitaria (FIS) of the Instituto de Salud Carlos III [PI10/1195, PS09/02620, PS09/02217]
- Generalitat Valenciana [ACOMP/2012/045]
- La Marato Fundation [090530]
- CDTI under the CENIT Programme
- Spanish Ministry of Science and Innovation
- Regional Ministry of Health of the Valencian Regional Government
- Carlos III Health Institute [CES10/030]
Ask authors/readers for more resources
A variety of nanoparticles have been proposed for several biomedical applications. To gauge the therapeutic potential of these nanoparticles, in vivo biodistribution is essential and mandatory. In the present study, ceria nanoparticles (5 nm average particle size) were labeled with F-18 to study their in vivo biodistribution in rats by positron emission tomography (PET). The F-18 isotope was anchored by reaction of N-succinimidyl 4-[F-18]fluorobenzoate (F-18-SFB) with a modified nanoparticle surface obtained by silylation with 3-aminopropylsilyl. Radiolabeled ceria nanoparticles accumulated mainly in lungs, spleen, and liver. Metabolic products of the radiolabeled nanoparticulate material were excreted into the urinary tract.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
